Clinical Trial Update: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KD025 for chronic graft-versus-host disease after at least two prior systemic therapies was terminated, with efficacy and safety result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• KD025

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: TERMINATED | Results posted: 2024-12-12